VENUSREM — Venus Remedies Share Price
- IN₹4.13bn
- IN₹3.19bn
- IN₹6.01bn
- 92
- 77
- 75
- 96
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 8.77 | ||
PEG Ratio (f) | 0.46 | ||
EPS Growth (f) | 23.75% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.84 | ||
Price to Tang. Book | 1.08 | ||
Price to Free Cashflow | 9.34 | ||
Price to Sales | 0.64 | ||
EV to EBITDA | 5 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 7.17% | ||
Return on Equity | 7.22% | ||
Operating Margin | 6.19% |
Financial Summary
Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | 3,393.34 | 5,481.23 | 5,986.5 | 5,555.1 | 6,014.5 | 6,722 | 7,461 | 13.32% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | -18.14 | -35.6 | +7.25 | +37.94 | +22.45 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Venus Remedies Limited is a research-driven pharmaceutical company. The Company is a global injectable manufacturer. It manufactures products catering to critical care segments such as antimicrobial resistance, anti-cancer, Anti-infective, Neurology, Skin and Wound Care, and Pain Management. With a diverse portfolio of products, the Company is dedicated to revolutionizing patient care through its specialized therapeutic segments such as anti-infective (antibiotics), oncology, neurology, pain management, and skin & wound care. The Company operates only in one business segment: Pharmaceutical Formulation and is engaged in manufacturing and trading of medicines. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, and others. It has three manufacturing facilities: Panchkula and Baddi in India and Werne in Germany.
Directors
- Pawan Chaudhary CHM (51)
- Neha Kodan CCO
- Manu Chaudhary MDR (45)
- Peeyush Jain DMD
- Ashutosh Jain EDR
- Suresh Chadha NID
- Pravindra Chauhan NID
- Savita Gupta NID (50)
- Navdeep Sud NID (61)
- Gilbert Wenzel NID (57)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 15th, 1989
- Public Since
- February 15th, 1995
- No. of Shareholders
- 20,386
- No. of Employees
- 1,187
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India
- Shares in Issue
- 13,366,988

- Address
- 51-52, Industrial Area, Phase-1, PANCHKULA, 134113
- Web
- https://www.venusremedies.com/
- Phone
- +91 1722933090
- Auditors
- Vinod Kumar & Associates
Upcoming Events for VENUSREM
Similar to VENUSREM
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 22:56 UTC, shares in Venus Remedies are trading at IN₹309.20. This share price information is delayed by 15 minutes.
Shares in Venus Remedies last closed at IN₹309.20 and the price had moved by -15.47% over the past 365 days. In terms of relative price strength the Venus Remedies share price has underperformed the S&P BSE 100 Index by -18.35% over the past year.
The overall consensus recommendation for Venus Remedies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreVenus Remedies does not currently pay a dividend.
Venus Remedies does not currently pay a dividend.
Venus Remedies does not currently pay a dividend.
To buy shares in Venus Remedies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹309.20, shares in Venus Remedies had a market capitalisation of IN₹4.13bn.
Here are the trading details for Venus Remedies:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: VENUSREM
Based on an overall assessment of its quality, value and momentum Venus Remedies is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Venus Remedies is IN₹399.00. That is 29.04% above the last closing price of IN₹309.20.
Analysts covering Venus Remedies currently have a consensus Earnings Per Share (EPS) forecast of IN₹29.40 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Venus Remedies. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -0.89%.
As of the last closing price of IN₹309.20, shares in Venus Remedies were trading -7.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Venus Remedies PE ratio based on its reported earnings over the past 12 months is 8.77. The shares last closed at IN₹309.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Venus Remedies' management team is headed by:
- Pawan Chaudhary - CHM
- Neha Kodan - CCO
- Manu Chaudhary - MDR
- Peeyush Jain - DMD
- Ashutosh Jain - EDR
- Suresh Chadha - NID
- Pravindra Chauhan - NID
- Savita Gupta - NID
- Navdeep Sud - NID
- Gilbert Wenzel - NID